RESUMO
Trophoblast expression of the non-classical MHC, HLA-G, is considered essential for feto-maternal immune tolerance and successful placentation in pregnancy. The HLA-G 14bp polymorphism in the 3'-untranslated region (UTR) of the HLA-G gene has been reported to be associated with development of pre-eclampsia (PE). In this study, maternal (peripheral blood, n=54) and fetal (cord blood, n=57) HLA-G 14bp genotypes have been determined by PCR in pre-eclamptic and normal pregnancies. In addition, HLA-G 14bp gene expression in decidua basalis (n=59) was analyzed by RT-PCR. The pre-eclamptic syndrome was neither associated with the HLA-G 14bp genotype (maternal or fetal), nor with altered decidual HLA-G 14bp gene expression. Furthermore, the HLA-G 14bp mRNA expressed in decidua basalis was of fetal origin and all potential transcripts, as predicted from the fetal HLA-G 14bp genotype, were expressed. In contrast to previous findings, we found no correlation between the HLA-G 14bp polymorphism and fetal growth. In conclusion, the fetal HLA-G 14bp genotype is reflected in the decidual HLA-G mRNA splice form profile, but does not appear to be associated with increased risk for development of PE.
Assuntos
Antígenos HLA/genética , Antígenos de Histocompatibilidade Classe I/genética , Polimorfismo Genético , Pré-Eclâmpsia/genética , Adulto , Alelos , Decídua/metabolismo , Feminino , Expressão Gênica , Predisposição Genética para Doença , Genótipo , Antígenos HLA/sangue , Antígenos HLA/metabolismo , Antígenos HLA-G , Antígenos de Histocompatibilidade Classe I/sangue , Antígenos de Histocompatibilidade Classe I/metabolismo , Humanos , Pré-Eclâmpsia/metabolismo , GravidezRESUMO
OBJECTIVE: The objective of the study was to test for a genetic association between the G-105A promoter polymorphism of the inflammatory mediator Selenoprotein S (SEPS1) and preeclampsia. STUDY DESIGN: A retrospective study in a large Norwegian case-control cohort compared maternal genotype and allele frequencies of the SEPS1 g.-105G>A polymorphism genotyped by SNPlex assay in preeclamptic (n = 1139) and control (n = 2269) women. Statistical significance was determined by chi2 and multivariate regression analyses. RESULTS: Women with preeclampsia were 1.34 times more likely to have the GA or AA genotype (P = .0039; 95% confidence interval [CI] 1.09 to 1.64) and 1.22 times more likely to carry the A allele (P = .023; odds ratio, 1.22; 95% CI, 1.02 to 1.46). CONCLUSION: The A allele of the SEPS1-105G>A polymorphism is a significant risk factor for preeclampsia in this population.